Top

Clinical and Translational Oncology

Published in:

01-08-2017 | Research Article

Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy

Authors: J. Xu, C. Ni, C. Ma, L. Zhang, X. Jing, C. Li, Y. Liu, X. Qu

Published in: Clinical and Translational Oncology | Issue 8/2017

Abstract

Purpose

Proinflammatory markers, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with many aspects of different malignancies. The aim of this study was to assess the associations of NLR and PLR with estrogen receptor (ER) and progesterone receptor (PR) expression in locally advanced breast cancer patients and their changes after neoadjuvant chemotherapy (NAC). Whether these parameters were predictive for the response to NAC in breast cancer patients was also evaluated.

Methods

132 Female primary locally advanced breast cancer patients treated with either ET (epirubicin–docetaxel), TEC (docetaxel–epirubicin–cyclophosphamide), or CEF (cyclophosphamide–epirubicin–fluorouracil) as NAC were retrospectively studied. NLR and PLR were calculated from peripheral blood cell count and their optimal cutoff levels were determined by receiver operating characteristic curves.

Results

The proportion of ER-positive breast cancers before NAC was higher both in NLR^low (<2.05) group and PLR^low group (<159.01). Changes in ER or PR expression level or status were observed in some patients. The alterations of NLR and PLR after NAC correlated with chemotherapy regimens, and elevated PLR was found. The patients with low pretreatment NLR (<1.67) or PLR (<151.27) had better responses to NAC than those with high NLR (≥1.67, 67.3 vs. 47.1%, P < 0.05) or PLR (≥151.27, 64.0 vs. 45.1%, P < 0.05).

Conclusions

The patients with low pretreatment NLR (<2.05) or PLR (<159.01) had higher ER expression. Changes in ER and PR expression status or level occured following NAC. Elevated PLR was found aft-NAC. Pretreatment NLR and PLR may be important predictive indicators for NAC response in breast cancer patients.

Available only for authorised users

Sinacki M, Badzio A, Welnicka-Jaskiewicz M, Bogaerts J, Piccart MJ, Therasse P, et al. Pattern of care in locally advanced breast cancer: focus on local therapy. Breast. 2011;20(2):145–50. doi:10.1016/j.breast.2010.08.008.CrossRefPubMed

Chavez-MacGregor M, Gonzalez-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol. 2010;12(7):461–7. doi:10.1007/s12094-010-0538-0.CrossRefPubMed

Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007;9(5):110. doi:10.1186/bcr1755.CrossRefPubMedPubMedCentral

Zhou X, Zhang J, Yun H, Shi R, Wang Y, Wang W, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015;6(34):36894–902. doi:10.18632/oncotarget.5050.CrossRefPubMedPubMedCentral

Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. Hum Pathol. 2014;45(2):249–58. doi:10.1016/j.humpath.2013.09.002.CrossRefPubMed

Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 2011;31(9):2995–8.PubMed

Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109(2):401–7. doi:10.1038/bjc.2013.350.CrossRefPubMedPubMedCentral

Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015;22(4):1377–84. doi:10.1245/s10434-014-4097-4.CrossRefPubMed

Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–6. doi:10.1245/s10434-014-4021-y.CrossRefPubMed

10.

Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? J BUON. 2015;20(3):714–22.PubMed

11.

Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON. 2013;18(1):57–63.PubMed

12.

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7. doi:10.1200/JOP.777003.CrossRefPubMedPubMedCentral

13.

Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol. 2012;138(6):796–802. doi:10.1309/AJCP6DKRND5CKVDD.CrossRefPubMed

14.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48.CrossRefPubMed

15.

Avci N, Deligonul A, Tolunay S, Cubukcu E, Olmez OF, Ulas A, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015;20(1):45–9.PubMed

16.

Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008;28(3B):1797–804.PubMed

17.

Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg. 2003;186(4):348–50.CrossRef

18.

Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10(1):91–8.CrossRef

19.

Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012;132(3):843–51. doi:10.1007/s10549-011-1660-6.CrossRefPubMed

20.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.CrossRefPubMedPubMedCentral

21.

Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–8. doi:10.1038/bjc.2015.183.CrossRefPubMedPubMedCentral

22.

Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55–9. doi:10.4048/jbc.2013.16.1.55.CrossRefPubMedPubMedCentral

23.

Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24. doi:10.1245/s10434-011-1814-0.CrossRefPubMed

24.

Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014;7:1743–52. doi:10.2147/OTT.S69657.CrossRefPubMedPubMedCentral

25.

Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432. doi:10.1007/s12032-012-0432-4.CrossRefPubMed

26.

Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, et al. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer. 2015;15:1027. doi:10.1186/s12885-015-2005-3.CrossRefPubMedPubMedCentral

27.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–10. doi:10.1245/s10434-015-4934-0.CrossRefPubMed

28.

Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320. doi:10.1186/s12885-016-2352-8.CrossRefPubMedPubMedCentral

29.

Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2014;15(18):7737–40.CrossRef

30.

Adachi K, Sakurai K, Suzuki S, Hara Y, Nagashima S, Hirano T, et al. Study of the response rate and neutrophil lymphocyte ratio in breast cancer patients undergoing neoadjuvant chemotherapy. Gan To Kagaku Ryoho. 2015;42(10):1283–5.PubMed

Title: Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy
Authors: J. Xu
C. Ni
C. Ma
L. Zhang
X. Jing
C. Li
Y. Liu
X. Qu
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1630-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis

Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study

The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review

The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers

MicroRNAs as prognostic biomarker and relapse indicator in leukemia

Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer